BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24961091)

  • 21. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.
    Fung AT; Reid SE; Jones MP; Healey PR; McCluskey PJ; Craig JC
    Br J Ophthalmol; 2007 Jan; 91(1):62-8. PubMed ID: 16956912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE; Lai J
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
    Walters TR
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension.
    Lee DA
    Clin Ther; 2000 Jan; 22(1):53-65. PubMed ID: 10688390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute and chronic effects of brimonidine 0.2% on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study.
    Vetrugno M; Maino A; Cantatore F; Ruggeri G; Cardia L
    Clin Ther; 2001 Sep; 23(9):1519-28. PubMed ID: 11589264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
    Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brimonidine tartrate: a one-month dose response study.
    Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
    Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies.
    Realini T; Nguyen QH; Katz G; DuBiner H
    Eye (Lond); 2013 Jul; 27(7):841-7. PubMed ID: 23640612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
    Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.
    Oztürk F; Ermiş SS; Inan UU; Aşagidag A; Yaman S
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma.
    Poinoosawmy D; Indar A; Bunce C; Garway-Heath DF; Hitchings RA
    Graefes Arch Clin Exp Ophthalmol; 2002 Sep; 240(9):721-6. PubMed ID: 12271368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
    Natt NK; Gupta A; Singh G; Singh T
    Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
    Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
    Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
    Lee DA; Gornbein J; Abrams C
    J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.